Welcome to DrugBank 4.0! If you prefer, you can still go back to version 3.0.
Identification
NamePotassium Chloride
Accession NumberDB00761  (APRD01322)
Typesmall molecule
Groupsapproved, withdrawn
Description

A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives.

Structure
Thumb
Synonyms
SynonymLanguageCode
Chlorid draselnyCzechNot Available
Chloride of potashNot AvailableNot Available
KaliumchloridNot AvailableNot Available
Monopotassium chlorideNot AvailableNot Available
Muriate of potashNot AvailableNot Available
SylviteNot AvailableNot Available
SaltsNot Available
Brand names
NameCompany
K-DurNot Available
Kaon ClNot Available
Klor-ConNot Available
KlotrixNot Available
Micro-KNot Available
Sando-KNot Available
Slow-KNot Available
Brand mixturesNot Available
CategoriesNot Available
CAS number7447-40-7
WeightAverage: 74.551
Monoisotopic: 73.932559568
Chemical FormulaClK
InChI KeyInChIKey=WCUXLLCKKVVCTQ-UHFFFAOYSA-M
InChI
InChI=1S/ClH.K/h1H;/q;+1/p-1
IUPAC Name
potassium chloride
SMILES
[Cl-].[K+]
Mass SpecNot Available
Taxonomy
KingdomInorganic Compounds
SuperclassMixed Metal/Non-metal Compounds
ClassAlkali Metal Salts
SubclassAlkali Metal Chlorides
Direct parentAlkali Metal Chlorides
Alternative parentsNot Available
SubstituentsNot Available
Classification descriptionThis compound belongs to the alkali metal chlorides. These are inorganic compounds in which the largest halogen atom is Chlorine, and the heaviest metal atom is an alkali metal.
Pharmacology
IndicationFor use as an electrolyte replenisher and in the treatment of hypokalemia.
PharmacodynamicsThe potassium ion is in the principle intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity, the transmission of nerve impulses, the contraction of cardiac, skeletal and smooth muscle, and the maintenance of normal renal function. The intracellular concentration of potassium is approximately 150 to 160 mEq per liter. The normal adult plasma concentration is 3.5 to 5 mEq per liter. An active ion transport system maintains this gradient across the plasma membrane. Potassium is a normal dietary constituent and under steady-state conditions the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine. The usual dietary intake of potassium is 50 to 100 mEq per day. Potassium depletion will occur whenever the rate of potassium loss through renal excretion and/or loss from the gastrointestinal tract exceeds the rate of potassium intake. Such depletion usually develops as a consequence of therapy with diuretics, primarily or secondary hyperaldosteronism, diabetic ketoacidosis, or inadequate replacement of potassium in patients on prolonged parenteral nutrition. Depletion can develop rapidly with severe diarrhea, especially if associated with vomiting. Potassium depletion due to these causes is usually accompanied by concomitant loss of chloride and is manifested by hypokalemia and metabolic alkalosis. Potassium depletion may produce weakness, fatigue, disturbances of cardiac rhythm (primarily ectopic beats), prominent U-waves in the electrocardiogram, and, in advanced cases, flaccid paralysis and/or impaired ability to concentrate urine. If potassium depletion associated with metabolic alkalosis cannot be managed by correcting the fundamental cause of the deficiency, e.g., where the patient requires long-term diuretic therapy, supplemental potassium in the form of high potassium food or potassium chloride may be able to restore normal potassium levels. In rare circumstances (e.g., patients with renal tubular acidosis) potassium depletion may be associated with metabolic acidosis and hyperchloremia. In such patients, potassium replacement should be accomplished with potassium salts other than the chloride, such as potassium bicarbonate, potassium citrate, potassium acetate, or potassium gluconate.
Mechanism of actionSupplemental potassium in the form of high potassium food or potassium chloride may be able to restore normal potassium levels.
AbsorptionPotassium is a normal dietary constituent and under steady-state conditions the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism
Route of eliminationPotassium is a normal dietary constituent and, under steady-state conditions, the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine. Potassium depletion will occur whenever the rate of potassium loss through renal excretion and/or loss from the gastrointestinal tract exceeds the rate of potassium intake.
Half lifeNot Available
ClearanceNot Available
ToxicityThe administration of oral potassium salts to persons with normal excretory mechanisms for potassium rarely causes serious hyperkalemia. However, if excretory mechanisms are impaired, of if potassium is administered too rapidly intravenously, potentially fatal hyperkalemia can result. It is important to recognize that hyperkalemia is usually asymptomatic and may be manifested only by an increased serum potassium concentration (6.5-8.0 mEq/L) and characteristic electrocardiographic changes (peaking of T-waves, loss of P-wave, depression of S-T segment, and prolongation of the QT interval). Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9-12 mEq/L).
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
Property Value Probability
Human Intestinal Absorption + 0.9445
Blood Brain Barrier + 0.975
Caco-2 permeable + 0.6764
P-glycoprotein substrate Non-substrate 0.9039
P-glycoprotein inhibitor I Non-inhibitor 0.9891
P-glycoprotein inhibitor II Non-inhibitor 0.9866
Renal organic cation transporter Non-inhibitor 0.9219
CYP450 2C9 substrate Non-substrate 0.8116
CYP450 2D6 substrate Non-substrate 0.717
CYP450 3A4 substrate Non-substrate 0.7571
CYP450 1A2 substrate Non-inhibitor 0.7551
CYP450 2C9 substrate Non-inhibitor 0.8594
CYP450 2D6 substrate Non-inhibitor 0.9314
CYP450 2C19 substrate Non-inhibitor 0.8365
CYP450 3A4 substrate Non-inhibitor 0.9576
CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9002
Ames test Non AMES toxic 0.6808
Carcinogenicity Carcinogens 0.7523
Biodegradation Ready biodegradable 0.6815
Rat acute toxicity 1.9786 LD50, mol/kg Not applicable
hERG inhibition (predictor I) Weak inhibitor 0.9433
hERG inhibition (predictor II) Non-inhibitor 0.9634
Pharmacoeconomics
Manufacturers
  • Novo nordisk inc
  • Savage laboratories inc div altana inc
  • Kv pharmaceutical co
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc florida
  • Abraxis pharmaceutical products
  • Akorn inc
  • App pharmaceuticals llc
  • B braun medical inc
  • Baxter healthcare corp anesthesia and critical care
  • Baxter healthcare corp
  • Gd searle llc
  • Hospira inc
  • International medication system
  • Eli lilly and co
  • Luitpold pharmaceuticals inc
  • Miles laboratories inc
  • Pharma serve inc sub torigian laboratories
  • Watson laboratories inc
  • Future pak ltd
  • Upsher smith laboratories inc
  • Apothecon inc div bristol myers squibb
  • Abbott laboratories pharmaceutical products div
  • Copley pharmaceutical inc
  • Eurand america inc
  • Schering corp
  • Novartis pharmaceuticals corp
  • Upsher-Smith Laboratories Inc.
Packagers
Dosage forms
FormRouteStrength
Capsule, extended releaseOral
LiquidIntravenous
LiquidOral
LiquidSublingual
Powder, for solutionOral
SolutionIntravenous
SolutionOral
Solution / dropsOral
TabletOral
Tablet, extended releaseOral
Prices
Unit descriptionCostUnit
Klor-Con 100 20meq Packets Box106.77USDbox
Kay Ciel 30 20meq Packets Box58.99USDbox
Rum-K-SF 15% Liquid 473ml Bottle45.98USDbottle
Klor-Con 30 25meq Packets Box36.99USDbox
Colyte 240 gm Solution26.0USDbottle
Colyte-Flavored 240 gm Solution18.17USDbottle
K-Lor 20meq Packets1.92USDpacket
K-lyte tablet eff1.43USDtablet
K-lyte-cl 25 meq tablet eff1.43USDtablet
Micro-K 10meq capsule1.41USDcapsule
Micro-K 8meq capsule1.21USDcapsule
Potassium cl 25 meq tablet eff0.94USDtablet
Micro-k 10 meq extencaps0.91USDeach
Potassium Chloride CR 10meq capsule0.9USDcapsule
Potassium Chloride CR 8meq capsule0.87USDcapsule
K-Tabs 10meq Controlled Release Tabs0.68USDtab
K-tab er 10 meq tablet0.66USDtablet
Kaochlor-eff 20 meq tablet0.59USDtablet
K-tab 10 meq tablet sa0.58USDtablet
K-Lyte 25 meq Effervescent Tablet0.58USDtablet
Klor-con m20 tablet0.57USDtablet
Klor-Con/EF 25meq Effervescent Tabs0.57USDtab
Klor-Con 8meq Controlled Release Tabs0.56USDtab
Klor-Con M20 20meq Controlled Release Tabs0.55USDtab
Potassium Chloride Crys CR 20meq Controlled Release Tabs0.53USDtab
Potassium cl 20 meq tablet er0.52USDtablet
Potassium cl 20 meq tablet sa0.52USDtablet
Klor-con 10 meq tablet0.5USDtablet
Klor-con m15 tablet0.5USDtablet
Klotrix 10meq Controlled Release Tabs0.5USDtab
Potassium cl er 20 meq tablet0.49USDtablet
Klor-con-ef 25 meq tablet eff0.4USDtablet
Micro-k 8 meq extencaps0.34USDeach
Kaon-Cl-10 10meq Controlled Release Tabs0.3USDtab
Klor-con m10 tablet0.3USDtablet
Potassium cl er 10 meq tablet0.3USDtablet
Potassium cl 10 meq tablet sa0.29USDtablet
Potassium Chloride Crys CR 10meq Controlled Release Tabs0.28USDtab
Potassium Chloride CR 10meq Controlled Release Tabs0.27USDtab
Potassium cl er 8 meq tablet0.26USDtablet
Kaon-cl 10 meq tablet sa0.23USDtablet
Potassium cl 2 meq/ml vial0.23USDml
K-Dur 20 meq Sustained-Release Tablet0.21USDtablet
Potassium Chloride CR 8meq Controlled Release Tabs0.18USDtab
Klor-con 8 meq tablet0.16USDtablet
Slow K 8 meq Sustained-Release Tablet0.16USDtablet
Micro-K Extencaps 8 meq Sustained-Release Capsule0.1USDcapsule
Apo-K 8 meq Sustained-Release Tablet0.09USDtablet
Potassium Chloride 40 Meq/15ml(20%) Liquid0.06USDml
Potassium Chloride 20 Meq/15ml(10%) Liquid0.03USDml
Potassium chloride crystals0.02USDg
K-10 Oral Liquid 1.33 meq/ml Liquid0.02USDml
Colyte with flavor packets0.01USDml
Pms - Potassium Chloride 1.33 meq/ml Liquid0.01USDml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
Statesolid
Experimental Properties
PropertyValueSource
melting point770 °CNot Available
water solubilityFreely solubleNot Available
Predicted Properties
PropertyValueSource
logP0.2ChemAxon
pKa (strongest acidic)-7ChemAxon
physiological charge-1ChemAxon
hydrogen acceptor count0ChemAxon
hydrogen donor count0ChemAxon
polar surface area0ChemAxon
rotatable bond count0ChemAxon
refractivity0ChemAxon
polarizability1.78ChemAxon
number of rings0ChemAxon
bioavailability1ChemAxon
rule of fiveYesChemAxon
Ghose filterNoChemAxon
Veber's ruleYesChemAxon
MDDR-like ruleNoChemAxon
Spectra
SpectraNot Available
References
Synthesis Reference

Fritz Hagedorn, Gerd Peuschel, Arno Singewald, “Method for the production of potassium chloride with K.sub.2 O content of more than 55 weight percent.” U.S. Patent US5057208, issued July, 1955.

US5057208
General ReferenceNot Available
External Links
ResourceLink
KEGG DrugD02060
PubChem Compound4873
PubChem Substance46506038
ChemSpider4707
ChEBI32588
ChEMBLCHEMBL1200731
Therapeutic Targets DatabaseDAP000828
PharmGKBPA451055
Drug Product Database2246134
RxListhttp://www.rxlist.com/cgi/generic4/microk-ls.htm
Drugs.comhttp://www.drugs.com/potassium_chloride.html
WikipediaPotassium_Chloride
ATC CodesA12BA01B05XA01
AHFS Codes
  • 88:29.00*
  • 40:12.00
  • 40:34.00*
  • 92:02.00*
PDB EntriesNot Available
FDA labelshow(632 KB)
MSDSshow(72.6 KB)
Interactions
Drug Interactions
Drug
ClidiniumAnticholinergic agents such as clidinium may enhance the ulcerogenic effect of potassium chloride. Solid oral dosage forms of potassium chloride are contraindicated in patients with impaired gastric emptying (e.g., due to the effects of drugs such as many anticholinergics). Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride; liquid or effervescent potassium preparations are possible alternatives.
TelmisartanPotassium Chloride may increase the hyperkalemic effect of Telmisartan. Monitor serum potassium levels during concomitant use.
TiotropiumThe ulcerative effects of solid oral dosage forms of KCl may be enhanced by Tiotropium, an anticholinergic. Anticholinergics slow gastric emptying, increasing the contact time between the gastrointestinal mucosa and KCl. Prolonged exposure to KCl increases the risk of gastric and intestinal irritation and ulceration. Solid oral dosage forms of KCl should be avoided; alternatives include liquid or effervescent potassium preparations.
TolterodineThe ulcerative effects of solid oral dosage forms of KCl may be enhanced by the anticholinergic, Tolterodine. Anticholinergics slow gastric emptying, increasing the contact time between the gastrointestinal mucosa and KCl. Prolonged exposure to KCl increases the risk of gastric and intestinal irritation and ulceration. Solid oral dosage forms of KCl should be avoided; alternatives include liquid or effervescent potassium preparations.
TrandolaprilThe potassium salt may increase the hyperkalemic effect of Trandolapril.
TrihexyphenidylThe ulcerative effects of solid oral dosage forms of KCl may be enhanced by Trihexyphenidyl, an anticholinergic. Anticholinergics slow gastric emptying, increasing the contact time between the gastrointestinal mucosa and KCl. Prolonged exposure to KCl increases the risk of gastric and intestinal irritation and ulceration. Solid oral dosage forms of KCl should be avoided; alternatives include liquid or effervescent potassium preparations.
TrimethobenzamideThe ulcerative effects of solid oral dosage forms of KCl may be enhanced by Trimethobenzamide, an anticholinergic. Anticholinergics slow gastric emptying, increasing the contact time between the gastrointestinal mucosa and KCl. Prolonged exposure to KCl increases the risk of gastric and intestinal irritation and ulceration. Solid oral dosage forms of KCl should be avoided; alternatives include liquid or effervescent potassium preparations.
TrospiumThe ulcerative effects of solid oral dosage forms of KCl may be enhanced by Trospium, an anticholinergic. Anticholinergics slow gastric emptying, increasing the contact time between the gastrointestinal mucosa and KCl. Prolonged exposure to KCl increases the risk of gastric and intestinal irritation and ulceration. Solid oral dosage forms of KCl should be avoided; alternatives include liquid or effervescent potassium preparations.
Food Interactions
  • Take with a full glass of water Take after a full meal.

1. Solute carrier family 12 member 2

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Solute carrier family 12 member 2 P55011 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Hebert SC: Bartter syndrome. Curr Opin Nephrol Hypertens. 2003 Sep;12(5):527-32. Pubmed

2. Solute carrier family 12 member 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: binder

Components

Name UniProt ID Details
Solute carrier family 12 member 1 Q13621 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Fujiwara TM, Bichet DG: Molecular biology of hereditary diabetes insipidus. J Am Soc Nephrol. 2005 Oct;16(10):2836-46. Epub 2005 Aug 10. Pubmed
  4. Bichet DG: Hereditary polyuric disorders: new concepts and differential diagnosis. Semin Nephrol. 2006 May;26(3):224-33. Pubmed
  5. Pressler CA, Heinzinger J, Jeck N, Waldegger P, Pechmann U, Reinalter S, Konrad M, Beetz R, Seyberth HW, Waldegger S: Late-onset manifestation of antenatal Bartter syndrome as a result of residual function of the mutated renal Na+-K+-2Cl- co-transporter. J Am Soc Nephrol. 2006 Aug;17(8):2136-42. Epub 2006 Jun 28. Pubmed
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

3. Solute carrier family 12 member 5

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Solute carrier family 12 member 5 Q9H2X9 Details

References:

  1. Takayama C, Inoue Y: Developmental localization of potassium chloride co-transporter 2 (KCC2) in the Purkinje cells of embryonic mouse cerebellum. Neurosci Res. 2007 Feb;57(2):322-5. Epub 2006 Nov 28. Pubmed
  2. Tornberg J, Segerstrale M, Kulesskaya N, Voikar V, Taira T, Airaksinen MS: KCC2-deficient mice show reduced sensitivity to diazepam, but normal alcohol-induced motor impairment, gaboxadol-induced sedation, and neurosteroid-induced hypnosis. Neuropsychopharmacology. 2007 Apr;32(4):911-8. Epub 2006 Aug 16. Pubmed
  3. Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. Pubmed
  4. Takayama C, Inoue Y: Developmental localization of potassium chloride co-transporter 2 in granule cells of the early postnatal mouse cerebellum with special reference to the synapse formation. Neuroscience. 2006 Dec;143(3):757-67. Epub 2006 Sep 27. Pubmed
  5. Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. Pubmed

4. Solute carrier family 12 member 6

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Solute carrier family 12 member 6 Q9UHW9 Details

References:

  1. Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. Pubmed
  2. Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. Pubmed
  3. Klein T, Cooper TG, Yeung CH: The role of potassium chloride cotransporters in murine and human sperm volume regulation. Biol Reprod. 2006 Dec;75(6):853-8. Epub 2006 Aug 30. Pubmed

5. Solute carrier family 12 member 7

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Solute carrier family 12 member 7 Q9Y666 Details

References:

  1. Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. Pubmed
  2. Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. Pubmed
  3. Klein T, Cooper TG, Yeung CH: The role of potassium chloride cotransporters in murine and human sperm volume regulation. Biol Reprod. 2006 Dec;75(6):853-8. Epub 2006 Aug 30. Pubmed

6. Solute carrier family 12 member 4

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Solute carrier family 12 member 4 Q9UP95 Details

References:

  1. Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. Pubmed
  2. Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. Pubmed
  3. Klein T, Cooper TG, Yeung CH: The role of potassium chloride cotransporters in murine and human sperm volume regulation. Biol Reprod. 2006 Dec;75(6):853-8. Epub 2006 Aug 30. Pubmed

1. Solute carrier family 12 member 2

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Solute carrier family 12 member 2 P55011 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Hebert SC: Bartter syndrome. Curr Opin Nephrol Hypertens. 2003 Sep;12(5):527-32. Pubmed

2. Solute carrier family 12 member 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Solute carrier family 12 member 1 Q13621 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Fujiwara TM, Bichet DG: Molecular biology of hereditary diabetes insipidus. J Am Soc Nephrol. 2005 Oct;16(10):2836-46. Epub 2005 Aug 10. Pubmed
  4. Bichet DG: Hereditary polyuric disorders: new concepts and differential diagnosis. Semin Nephrol. 2006 May;26(3):224-33. Pubmed
  5. Pressler CA, Heinzinger J, Jeck N, Waldegger P, Pechmann U, Reinalter S, Konrad M, Beetz R, Seyberth HW, Waldegger S: Late-onset manifestation of antenatal Bartter syndrome as a result of residual function of the mutated renal Na+-K+-2Cl- co-transporter. J Am Soc Nephrol. 2006 Aug;17(8):2136-42. Epub 2006 Jun 28. Pubmed
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

3. Solute carrier family 12 member 5

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Solute carrier family 12 member 5 Q9H2X9 Details

References:

  1. Takayama C, Inoue Y: Developmental localization of potassium chloride co-transporter 2 (KCC2) in the Purkinje cells of embryonic mouse cerebellum. Neurosci Res. 2007 Feb;57(2):322-5. Epub 2006 Nov 28. Pubmed
  2. Tornberg J, Segerstrale M, Kulesskaya N, Voikar V, Taira T, Airaksinen MS: KCC2-deficient mice show reduced sensitivity to diazepam, but normal alcohol-induced motor impairment, gaboxadol-induced sedation, and neurosteroid-induced hypnosis. Neuropsychopharmacology. 2007 Apr;32(4):911-8. Epub 2006 Aug 16. Pubmed
  3. Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. Pubmed
  4. Takayama C, Inoue Y: Developmental localization of potassium chloride co-transporter 2 in granule cells of the early postnatal mouse cerebellum with special reference to the synapse formation. Neuroscience. 2006 Dec;143(3):757-67. Epub 2006 Sep 27. Pubmed
  5. Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. Pubmed

4. Solute carrier family 12 member 6

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Solute carrier family 12 member 6 Q9UHW9 Details

References:

  1. Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. Pubmed
  2. Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. Pubmed
  3. Klein T, Cooper TG, Yeung CH: The role of potassium chloride cotransporters in murine and human sperm volume regulation. Biol Reprod. 2006 Dec;75(6):853-8. Epub 2006 Aug 30. Pubmed

5. Solute carrier family 12 member 7

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Solute carrier family 12 member 7 Q9Y666 Details

References:

  1. Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. Pubmed
  2. Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. Pubmed
  3. Klein T, Cooper TG, Yeung CH: The role of potassium chloride cotransporters in murine and human sperm volume regulation. Biol Reprod. 2006 Dec;75(6):853-8. Epub 2006 Aug 30. Pubmed

6. Solute carrier family 12 member 4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Solute carrier family 12 member 4 Q9UP95 Details

References:

  1. Misri S, Chimote AA, Adragna NC, Warwar R, Brown TL, Lauf PK: KCC isoforms in a human lens epithelial cell line (B3) and lens tissue extracts. Exp Eye Res. 2006 Nov;83(5):1287-94. Epub 2006 Sep 1. Pubmed
  2. Capo-Aponte JE, Wang Z, Bildin VN, Iserovich P, Pan Z, Zhang F, Pokorny KS, Reinach PS: Functional and molecular characterization of multiple K-Cl cotransporter isoforms in corneal epithelial cells. Exp Eye Res. 2007 Jun;84(6):1090-103. Epub 2007 Feb 16. Pubmed
  3. Klein T, Cooper TG, Yeung CH: The role of potassium chloride cotransporters in murine and human sperm volume regulation. Biol Reprod. 2006 Dec;75(6):853-8. Epub 2006 Aug 30. Pubmed

Comments
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:12